Patent intelligence · US
US 12145943
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
Patent details — US 12145943
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 19, 2024
- Expiration
- Nov 14, 2044
- Applicant
- ACTUATE THERAPEUTICS INC.
- Claims
- 5
- CPC classes
- A61P, A61P35/00
Quick answer
US 12145943 (Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione) is held by ACTUATE THERAPEUTICS INC.. Status: granted. Granted Nov 19, 2024. Expires Nov 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ACTUATE THERAPEUTICS INC.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61P, A61P35/00
More from ACTUATE THERAPEUTICS INC.
Related pharmaceutical patents in our USPTO index.
-
US 12116374
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 12083098
Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors
granted -
US 11980607
Methods of treating malignant lymphoproliferative disorders
granted -
US 11510904
Methods of treating malignant lymphoproliferative disorders
granted -
US 11407759
Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 11136334
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted
Frequently asked questions
What is US patent 12145943?
US 12145943 (Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione) is held by ACTUATE THERAPEUTICS INC.. Status: granted. Granted Nov 19, 2024. Expires Nov 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12145943?
ACTUATE THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 12145943 expire?
Our index shows an expiration date of Nov 14, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.